Table 2 Primary end-point, main inclusion criteria and estimated enrollment of ongoing phase 3 trials that include patients progressing on lenalidomide

CANDOR (NCT03158688):

 Objective:

 -To compare Kd, and Daratumumab-Kd in terms of PFS in patients with MM who have relapsed after 1 to 3 prior therapies.

 Main inclusion criteria:

 -Relapsed or progressive MM after last treatment

 -Received at least 1, but not more than 3 prior lines of therapy for MM

 Estimated enrollment: 466 patients

IKEMA (NCT03275285):

 Objective:

 -To compare Kd, and Isatuximab-Kd in terms of PFS in patients with MM who have relapsed after 1 to 3 prior therapies.

 Main inclusion criteria:

 -Patients with MM previously treated with prior 1 to 3 lines

 Estimated enrollment: 300 patients

ICARIA (NCT 02990338):

 Objective:

 -To compare Pom-dex, and Isatuximab-Pom-dex in terms of PFS in patients with RRMM

 Main inclusion criteria:

 -Patients must have received at least 2 prior lines of anti-myeloma therapy

 -Patients must have failed treatment with lenalidomide and a proteasome inhibitor

 -Patients must have progressed on or within 60 days after end of previous therapy before study entry, i.e., refractory to the last line of treatment

 Estimated enrollment: 300 patients

APPOLLO / EMN14 (NCT 03180736):

 Objective:

 -To compare Pom-dex, and Daratumumab-Pom-dex in terms of PFS in patients with RRMM

 Main inclusion criteria:

 -Subjects must have received prior anti-myeloma treatment. The prior treatment must have included both a PI- and lenalidomide-containing regimen. The subject must have had a response to prior therapy

 -Subjects must have documented evidence of PD on or after the last regimen

 -Subjects who received only 1 line of prior treatment must have demonstrated PD on or within 60 days of completion of the lenalidomide-containing regimen

 Estimated enrollment: 302 patients

BOSTON (NCT03110562):

 Objective:

 -To compare Vd, and Vd-Selinexor in terms of PFS in patients with RRMM

 Main inclusion criteria

 -Patients must have received at least 1 prior anti-MM regimen and no more than 3 prior anti-MM regimens

 -Documented evidence of progressive MM on or after their most recent regimen

 Estimated enrollment: 364 patients

BELLINI (NCT02755597):

 Objective:

 -To compare Vd-placebo, and Vd-Venetoclax in terms of PFS in patients with RRMM

 Main inclusion criteria

 -Participant has documented relapsed or progressive MM on or after any regimen, or refractory to the most recent line of therapy

 -Participant must have received prior treatment with at least one, but no more than three prior lines of therapy for MM

 Estimated enrollment: 291 patients